A nose for trouble.

A 63‑year‑old Caucasian non‑smoker presented with purplish, firm, slowly growing plaques on the nose, of 20 years duration. The bigger one involved the upper part of the nose in its entirety [Figure 1], while there were smaller ones on the left and right cheek. All the plaques were asymptomatic and did not worsen after sunlight exposure. His past medical history was unremarkable. Hematological and biochemical parameters were within normal limits. Histological examination revealed a diffuse mid‑dermal cellular infiltrate composed of neutrophils, eosinophils, plasma cells, and lymphocytes. A narrow Grenz zone was present. In the lower part of the reticular dermis, the mixed infiltrate was intermingled with a massive deposition of fascicled pattern collagen fibers and spindle cell

SIMULTANEOUS STIMATION OF ASPIRIN AND OMEPRAZOLE (Y0SPRALA) IN BULK BY UV-SPECTROSCOPY

In India, there are roughly 30 million heart patients and two lakh surgeries are being performed every year. YOSPRALA-a new emerging drug approved by USFDA in September 2016 to treat Ischemic stroke, prophylaxis and gastric ulcer prophylaxis. The active ingredients present are Aspirin and Omeprazole.Hence ana attempt is made to develop a new analytical method for Simultaneous estimation of Aspirin and Omeprazole using methanol as solvent The Absorption maxima of Aspirin and Omeprazole was at 224nm and 251.8nm respectively. Linearity range for aspirin was 0.5-25µg/ml with regression co-efficient-099 and omeprazole was 1-8µg/ml with regression coefficient 0.992. The method was validated for precision and %RSD was less than 1.5% for both aspirin and omeprazole. The proposed method was statistically validated for standard deviation, relative standard deviation.coefficient of variance and the results were within the limits. Hence the above method was simple, cost effective, robust and can be used for routine analysis in in pharmaceutical preparations. Keywords: Yosprala, Aspirin and Omeprazole, UV spectroscopy

Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain

Metastases represent the most common brain tumors in adults. Surgical resection alone results in 45% recurrence and is usually accompanied by radiation and chemotherapy. Adequate chemotherapy delivery to the CNS is hindered by the blood–brain barrier. Efforts at delivering chemotherapy locally to gliomas have shown modest increases in survival, likely limited by the infiltrative nature of the tumor. Temozolomide (TMZ) is first-line treatment for gliomas and recurrent brain metastases. Doxorubicin (DOX) is used in treating many types of breast cancer, although its use is limited by severe cardiac toxicity. Intracranially implanted DOX and TMZ microcapsules are compared with systemic administration of the same treatments in a rodent model of breast adenocarcinoma brain metastases. Outcomes were animal survival, quantified drug exposure, and distribution of cleaved caspase 3. Intracranial delivery of TMZ and systemic DOX administration prolong survival more than intracranial DOX or systemic TMZ. Intracranial TMZ generates the more robust induction of apoptotic pathways. We postulate that these differences may be explained by distribution profiles of each drug when administered intracranially: TMZ displays a broader distribution profile than DOX. These microcapsule devices provide a safe, reliable vehicle for intracranial chemotherapy delivery and have the capacity to be efficacious and superior to systemic delivery of chemotherapy. Future work should include strategies to improve the distribution profile. These findings also have broader implications in localized drug delivery to all tissue, because the efficacy of a drug will always be limited by its ability to diffuse into surrounding tissue past its delivery source.National Institutes of Health (U.S.) (Grant R01 EB006365-06)Brain Science Foundation (Private Grant 106708

VALUTAZIONE DEL KIT LIAISON TTG IGA NELLA DETERMINAZIONE DI ANTICORPI ANTI-TRANSGLUTAMINASI.

n/